Treatment results and prognostic factors in primary thyroid lymphoma patients: A Rare Cancer Network study

Annals of Oncology

Volumn 22, Issue 1, 2011, Pages 156-164

  Onal, C ^a   Li, Y X ^b   Miller, R C ^c   Poortmans, P ^d   Constantinou, N ^e   Weber, D C ^f   Atasoy, B M ^g   Igdem, S ^h   Ozsahin, M ⁱ   Ozyar, E ^j  

^a BASKENT UNIVERSITY   (Turkey)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c MAYO CLINIC   (United States)

^d Institute Verbeeten   (Netherlands)

^e THEAGENIO CANCER HOSPITAL   (Greece)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^h Metropolitan Hospital   (Turkey)

ⁱ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^j ACIBADEM UNIVERSITY   (Turkey)

more..

Author keywords

Chemotherapy; Combined modality treatment; Non Hodgkin's lymphoma; Prognostic factors; Radiotherapy; Thyroid lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; SYMPTOMATOLOGY; THYROID LYMPHOMA; THYROIDECTOMY; THYROIDITIS; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 78650394510     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq310     Document Type: Article

References (33)

1. Austin JR, el-Naggar AK, Goepfert H. Thyroid cancers. II. Medullary, anaplastic, lymphoma, sarcoma, squamous cell. Otolaryngol Clin North Am 1996; 29: 611-627.
2. Aozasa K, Tsujimoto M, Sakurai M et al. Non-Hodgkin's lymphomas in Osaka, Japan. Eur J Cancer Clin Oncol 1985; 21: 487-492.
3. Singer JA. Primary lymphoma of the thyroid. Am Surg 1998; 64: 334-337.
4. Ansell SM, Grant CS, Habermann TM. Primary thyroid lymphoma. Semin Oncol 1999; 26: 316-323.
5. Kato I, Tajima K, Suchi T et al. Chronic thyroiditis as a risk factor of B-cell lymphoma in the thyroid gland. Jpn J Cancer Res 1985; 76: 1085-1090.
6. Pedersen RK, Pedersen NT. Primary non-Hodgkin's lymphoma of the thyroid gland: a population based study. Histopathology 1996; 28: 25-32.
7. Laing RW, Hoskin P, Hudson BV et al. The significance of MALT histology in thyroid lymphoma: a review of patients from the BNLI and Royal Marsden Hospital. Clin Oncol (R Coll Radiol) 1994; 6: 300-304.
8. Klyachkin ML, Schwartz RW, Cibull M et al. Thyroid lymphoma: is there a role for surgery? Am Surg 1998; 64: 234-238.
9. Tupchong L, Hughes F, Harmer CL. Primary lymphoma of the thyroid: clinical features, prognostic factors, and results of treatment. Int J Radiat Oncol Biol Phys 1986; 12: 1813-1821.
10. Blair TJ, Evans RG, Buskirk SJ et al. Radiotherapeutic management of primary thyroid lymphoma. Int J Radiat Oncol Biol Phys 1985; 11: 365-370.
11. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
12. Sehn LH, Donaldson J, Chhanabhai M et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027-5033.
13. Scholefield JH, Quayle AR, Harris SC, Talbot CH. Primary lymphoma of the thyroid, the association with Hashimoto's thyroiditis. Eur J Surg Oncol 1992; 18: 89-92.
14. Carbone PP, Kaplan HS, Musshoff K et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860-1861.
15. DiBiase SJ, Grigsby PW, Guo C et al. Outcome analysis for stage IE and IIE thyroid lymphoma. Am J Clin Oncol 2004; 27: 178-184.
16. Logue JP, Hale RJ, Stewart AL et al. Primary malignant lymphoma of the thyroid: a clinicopathological analysis. Int J Radiat Oncol Biol Phys 1992; 22: 929-933.
17. Tsang RW, Gospodarowicz MK, Pintilie M et al. Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys 2001; 50: 1258-1264.
18. Dawson IM, Cornes JS, Morson BC. Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. Br J Surg 1961; 49: 80-89.
19. Williams ED. Malignant lymphoma of the thyroid. Clin Endocrinol Metab 1981; 10: 379-389.
20. Belal AA, Allam A, Kandil A et al. Primary thyroid lymphoma: a retrospective analysis of prognostic factors and treatment outcome for localized intermediate and high grade lymphoma. Am J Clin Oncol 2001; 24: 299-305.
21. Thieblemont C, Mayer A, Dumontet C et al. Primary thyroid lymphoma is a heterogeneous disease. J Clin Endocrinol Metab 2002; 87: 105-111.
22. Derringer GA, Thompson LD, Frommelt RA et al. Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol 2000; 24: 623-639.
23. Wirtzfeld DA, Winston JS, Hicks WL Jr, Loree TR. Clinical presentation and treatment of non-Hodgkin's lymphoma of the thyroid gland. Ann Surg Oncol 2001; 8: 338-341.
24. Niitsu N, Okamoto M, Nakamura N et al. Clinicopathologic correlations of stage IE/IIE primary thyroid diffuse large B-cell lymphoma. Ann Oncol 2007; 18: 1203-1208.
25. Tilly H, Dreyling M. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl 4): 110-112.
26. Tsang RW, Gospodarowicz MK, Pintilie M et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003; 21: 4157-4164.
27. Rosen IB, Sutcliffe SB, Gospodarowicz MK et al. The role of surgery in the management of thyroid lymphoma. Surgery 1988; 104: 1095-1099.
28. Ha CS, Shadle KM, Medeiros LJ et al. Localized non-Hodgkin lymphoma involving the thyroid gland. Cancer 2001; 91: 629-635.
29. Horning SJ, Weller E, Kim K et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004; 22: 3032-3038.
30. Miller TP, Dahlberg S, Cassady JR et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339: 21-26.
31. Doria R, Jekel JF, Cooper DL. Thyroid lymphoma. The case for combined modality therapy. Cancer 1994; 73: 200-206.
32. Persky DO, Unger JM, Spier CM et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 2008; 26: 2258-2263.
33. Bari A, Marcheselli L, Sacchi S et al. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol 2010; 21: 1486-1491.